These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 28115082)

  • 41. Toward population management in an integrated care model.
    Maddux FW; McMurray S; Nissenson AR
    Blood Purif; 2013; 36(3-4):152-9. PubMed ID: 24496184
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diabetes prevention, health information technology, and meaningful use: challenges and opportunities.
    Ahmad FS; Tsang T
    Am J Prev Med; 2013 Apr; 44(4 Suppl 4):S357-63. PubMed ID: 23498299
    [TBL] [Abstract][Full Text] [Related]  

  • 43. First hemodialysis access selection varies with patient acuity.
    Friedman AL; Walworth C; Meehan C; Wander H; Shemin D; DeSoi W; Kitsen J; Hill C; Lambert C; Mesler D
    Adv Ren Replace Ther; 2000 Oct; 7(4 Suppl 1):S4-10. PubMed ID: 11053581
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Medicare Program; Prospective Payment System and Consolidated Billing for Skilled Nursing Facilities for FY 2018, SNF Value-Based Purchasing Program, SNF Quality Reporting Program, Survey Team Composition, and Correction of the Performance Period for the NHSN HCP Influenza Vaccination Immunization Reporting Measure in the ESRD QIP for PY 2020. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2017 Aug; 82(149):36530-634. PubMed ID: 28805359
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Challenges and directions for Medicare ESRD payment policy.
    Ray NF; Ross M
    Semin Nephrol; 2000 Nov; 20(6):565-76. PubMed ID: 11111858
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Quality improvement and pay for performance: barriers to and strategies for success.
    Cohen RI; Jaffrey F; Reitzner JB; Baumann MH
    Chest; 2013 Jun; 143(6):1542-1547. PubMed ID: 23732583
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Medicare program; end-stage renal disease prospective payment system, quality incentive program, and bad debt reductions for all Medicare providers. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2012 Nov; 77(218):67450-531. PubMed ID: 23139948
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Matter of Choice: Opportunities and Obstacles Facing People with ESRD.
    Feder J; Nadel MV; Krishnan M
    Clin J Am Soc Nephrol; 2016 Mar; 11(3):536-8. PubMed ID: 26553796
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Implementing the Health Care Quality Improvement Program in the Medicare ESRD Program: a new era of quality improvement in ESRD.
    McClellan WM; Helgerson SD; Frederick PR; Wish JB; McMullan M
    Adv Ren Replace Ther; 1995 Apr; 2(2):89-94. PubMed ID: 7614353
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CMS quality measures report finds improvement.
    Hosp Peer Rev; 2015 Apr; 40(4):37-9. PubMed ID: 25898493
    [No Abstract]   [Full Text] [Related]  

  • 51. Perpetuating sub-optimal care: CMS, QIPs, and the hemoglobin myth.
    Pollak SP; Lorch JA; Pollak VE
    Nephrol News Issues; 2012 Jan; 26(1):30, 32-4. PubMed ID: 22359963
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Funding Innovative Dialysis Technology in the United States: Home Dialysis and the ESRD Transitional Add-on Payment for New and Innovative Equipment and Supplies (TPNIES).
    Reddy YNV; Mendu ML; Weinhandl ED
    Am J Kidney Dis; 2021 Dec; 78(6):892-896. PubMed ID: 34051309
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Can dialysis therapy be improved? A report from the ESRD Core Indicators Project.
    McClellan WM; Frankenfield DL; Frederick PR; Flanders WD; Alfaro-Correa A; Rocco M; Helgerson SD
    Am J Kidney Dis; 1999 Dec; 34(6):1075-82. PubMed ID: 10585317
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The organization and financing of kidney dialysis and transplant care in the United States of America.
    Hirth RA
    Int J Health Care Finance Econ; 2007 Dec; 7(4):301-18. PubMed ID: 17602296
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Medicare program; end-stage renal disease (ESRD) payment exception requests and organ procurement costs--HCFA. Final rule.
    Fed Regist; 1997 Aug; 62(158):43657-74. PubMed ID: 10169837
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pay-for-performance programs effectiveness in healthcare: the case of the end-stage renal disease quality incentive program.
    Piri S
    Eur J Health Econ; 2024 Mar; 25(2):221-236. PubMed ID: 36966480
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Excess Death Estimates in Patients with End-Stage Renal Disease - United States, February-August 2020.
    Ziemba R; Campbell KN; Yang TH; Schaeffer SE; Mayo KM; McGann P; Quinn S; Roach J; Huff ED
    MMWR Morb Mortal Wkly Rep; 2021 Jun; 70(22):825-829. PubMed ID: 34081687
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Medicare program; End Stage Renal Disease Program; redesignation of networks and reorganization of network organizations--HCFA. Final rule.
    Fed Regist; 1986 Aug; 51(165):30356-62. PubMed ID: 10300986
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The impact of the bundle on lab services.
    Burney M
    Nephrol News Issues; 2011 Jul; 25(8):14-5. PubMed ID: 21877618
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Excluded from universal coverage: ESRD patients not covered by Medicare.
    Thamer M; Ray NF; Richard C; Greer JW; Pearson BC; Cotter DJ
    Health Care Financ Rev; 1995; 17(2):123-46. PubMed ID: 10157372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.